Chlamydia pneumoniae, a common cause of respiratory infection, is vasotropic and frequently found in human atheromas. Whether it plays a causal role in coronary artery disease (CAD) is uncertain. The effects of 3 months of azithromycin treatment or placebo were tested in 302 patients with chronic CAD seropositive to C. pneumoniae at 3-6 months. Azithromycin reduced a global rank sum score of 4 inflammatory markers (C-reactive protein [CRP], interleukin [IL]-1, IL-6, tumor necrosis factor-a;
Entry criteria. The principal inclusion criteria were previous myocardial infarction (MI), coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), and angiographic CAD (150% stenosis of у1 major coronary artery). Patients were required to be у18 years of age (no upper limit), to have a life expectancy of у2 years, and to have a C. pneumoniae IgG titer (microimmunofluorescence test) of у1:16. Selected exclusion criteria were New York Heart Association functional class III or IV heart failure, ejection fraction !25%, MI within 5 days, bypass surgery within 1 month, or PCI within 3 months. Planned CABG or PCI was a further exclusion as was need for concurrent macrolide use or macrolide contraindication.
Laboratory hypotheses. The primary laboratory hypothesis was that azithromycin would reduce a global index of inflammation at 3 (primary) and 6 months. The null hypothesis was that there would be no difference in azithromycin and placebo groups in the global change scores by use of the O'Brien nonparametric rank sum test for the 4 markers. The secondary hypothesis was that the individual markers (C-reactive protein [CRP] , interleukin [IL]-1, IL-6, and tumor necrosis factor-1a) would be reduced (90% power for 0.38 SD difference). Another secondary hypothesis was that azithromycin compared to placebo would reduce anti-C. pneumoniae IgG and IgA levels at 6 months.
Clinical hypotheses. We postulated that azithromycin, compared with placebo, would reduce cardiovascular events at 6 months (secondary end point) and 2 years (primary end point). The components of this composite end point included cardiovascular death, nonfatal MI, resuscitated cardiac arrest, hospitalization for unstable angina, unplanned revascularization (PCI, CABG), and nonfatal stroke. By using the control event rate provided by Gupta et al. [10] , we postulated that the study (at 2 years) would have 90% power to detect a 50% reduction in event rate, from 28% to 14%, with about 300 patients.
Other prespecified end points. Additional prespecified end points included the rate of infections requiring antibiotics, comparative adverse event rates, and comparative discontinuation rates (within 3 months). [12] .
a Primary end point.
Results
Baseline characteristics. Of 430 patients who were screened, 333 (77%) had positive C. pneumoniae serology and 302 gave informed consent and were enrolled in the study (150 assigned to azithromycin, 152 to placebo). Baseline characteristics are shown in table 1. Overall, patients were a mean of 64 years old; 89% were men; 60% had suffered a previous MI, 46% had undergone bypass surgery, and 46%, a PCI. Characteristics were well balanced between groups. Baseline levels of inflammatory markers and antichlamydial antibody levels (shown in table 2) did not differ between groups.
Effect of therapy on global inflammatory scores. Table 3 shows the primary laboratory results. At 6, but not 3 months, average global rank sum score was reduced 11% (from 598 to 532 rank units, ). Similarly, global rank sum change P = .011 score was reduced at 6 (but not 3) months by 10% (from 587 to 531 rank units, ). P = .027 Changes in individual markers at 6 months for CRP, IL-1, and IL-6. The mean rank of the CRP change score was reduced by 15% (from 150 to 128, ). Similarly, the mean rank P = .017 of the IL-6 change score was reduced by 15% (from 118 to 139, ). Finally, the median IL-1 levels were reduced at 6 P = .023 months in the azithromycin (1.45 pg/mL) compared with the placebo group (2.20 pg/mL), . P = .027 Effect of therapy on clinical events at 6 months. Table 4 shows individual and composite events at 6 months (secondary end point). A total of 16 events occurred, 9 in the azithromycin group and 7 in the placebo group ( ). The distribution P = .60 of events was generally similar in the 2 groups.
Effect of therapy on other end points. No differences in quantitative measures of anti-C. pneumoniae IgG or IgA were observed at 3 or 6 months. At baseline, antibody levels were similar in the azithromycin and placebo groups (median, 2.95 and 2.79 relative value units [rvu] for IgG and 2.66 and 2.82 for IgA, respectively; for both comparisons). Levels were P 1 .6 unchanged and similar at 6 months in both groups (median change, 0 and Ϫ0.05 rvu for IgG and 0.16 and 0.11 rvu for IgA;
for both comparisons). P у . 4 Azithromycin reduced the number of clinical infections over the 3-month treatment period (12 vs. 27, ), including P = .011 those requiring antibiotics (1 vs. 12, ). Two patients in P = .002 the active therapy group developed a secondary yeast (candidal) infection requiring treatment. Otherwise, tolerance was good and compliance excellent. An increase in mild-to-moderate, mostly gastrointestinal, side effects was seen in the active therapy group (primarily nausea, diarrhea, flatulence).
Discussion and Conclusions
Our moderately large, double-blind, randomized, secondary prevention study in CAD patients seropositive to C. pneumoniae showed a 10%-11% reduction in global inflammatory marker scores at the end of the 6 months (but not 3 months) for change scores (P = .03) and absolute value scores (
). All indi-P = .01 vidual measures trended in a favorable direction, with significance reached for CRP, IL-1, and IL-6. C. pneumoniae antibody titers were unaffected by therapy, in keeping with the results of one study [11] but not another [10] .
We were surprised to find a delay in the changes in inflammatory markers with antibiotic therapy; effects were evident at 6 but not 3 months. The lack in difference at 3 months was due to a transient decline in the placebo group rather than to a failure of the markers to decline in the azithromycin group. We have no good explanation for this but speculate that generalized reductions in inflammatory markers at 3 months might relate to better medical treatment (treatment of infections, aspirin use, lipid-lowering therapies) during the double-blind treatment phase (first 3 months) of the study.
The study design does not permit us to determine whether the anti-inflammatory effects of azithromycin are due to a specific antichlamydial action or a more general anti-infectious or anti-inflammatory effect. A similar uncertainty applies to the cause of the reported benefits of minocycline therapy in rheumatoid arthritis [13] . The temporal disparity between the reduction in clinical infections (over the first 3 months, during active therapy) and the reduction in inflammatory markers (first seen at 6 months) argues against an acute anti-infectious effect as the primary explanation. We found no difference in clinical events at 6 months. Results of two earlier smaller studies thus appear overly enthusiastic for effects of antibiotics on early events [10, 11] . Other observations in the ACADEMIC study included the generally good tolerance of azithromycin and the reduced rate of infections, including those requiring antibiotics, during the 3 months of active therapy.
Although our 6-month secondary end point for cardiovascular events shows no difference, we recognize its low power and await our 2-year primary end point result. If changes in inflammatory markers precede (and predict) changes in the risk of future clinical events, then treatment periods longer than 3 months, as proposed for the Azithromycin Coronary Events Study (ACES) [4] , may be required for optimal clinical benefit.
Even when events from all 3 studies to date are combined, only a limited number of events have occurred (
). These n = 48 suggest the possibility of about a 30% reduction in events, a trend that is not significant, given the limited data. Table 5 shows an overview of the early clinical events (within 6-18 months) in these 3 trials [10] [11] [12] 14] in 564 patients followed for 6-18 months: 7.2% of those treated with antibiotics (azithromycin or roxithromycin) and 9.9% treated by placebo had a cardiovascular event, odds ratio 0.71 (95% confidence interval, 0.39-1.30; significant). P = not In conclusion, we believe our findings should encourage larger and longer-term clinical trials (i.e., the WIZARD [Weekly Intervention with Zithromax against Atherosclerotic-Related Disorders] and ACES studies) [15] . The intriguing finding of a reduction in inflammatory markers at 6 but not 3 months could be interpreted to suggest that these marker changes reflect an effect of antibiotics on chronic indolent infection (chlamydial vasculitis?) rather than acute infection (where antibiotics would be expected to have maximal impact at or before 3 months). If this is true, then the effect of therapy on cardiovascular events may be greater after 6 months, raising interest in our 2-year results and the results of the longer-term and larger WIZARD and ACES studies. Meanwhile, the C. pneumoniae hypothesis of coronary atherogenesis remains to be proven.
